Shilpa Medicare fell 3.62% to Rs 498.35 after the company s consolidated net profit slumped 77.35% to Rs 7.83 crore on 5.44% decrease in revenue from operations to Rs 208.03 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax tanked 79.79% to Rs 8.40 crore in Q4 FY21 as against Rs 41.57 crore in Q4 FY20. The Q4 earnings was declared at the fag end of market hours yesterday, 31 May 2021.
EBITDA skid 39% to Rs 33.12 crore in Q4 FY21 as against Rs 54.50 crore over the same period last year. EBITDA margin stood at 15% in Q4 March 2021 from 24% in Q4 March 2020.
During the financial year, Shilpa Medicare s consolidated net profit declined 5.36% to Rs 147.78 crore on 0.75% slip in revenue from operations to Rs 901.13 crore in FY 2021 over FY 2020.
Read more about Divis Lab Q4 PAT rises 29% YoY to Rs 502 cr on Business Standard. On a consolidated basis, Divi s Laboratories posted a 29.3% rise in net profit to Rs 502.02 crore in Q4 FY21 compared with Rs 388.23 crore in Q4 FY20.
Read more about Ipca Lab Q4 PAT spurts 94% YoY to Rs 161 cr on Business Standard. On a consolidated basis, Ipca Laboratories recorded 94% jump in net profit to Rs 161.20 crore in Q4 FY21 as against Rs 83.05 crore in Q4 FY20.